China Accepts AP301 NDA

Company: Alebund Pharmaceuticals · Event Type: NDA Acceptance · Product: AP301 · Indication: Hyperphosphatemia in Maintenance-Dialysis Patients with Chronic Kidney Disease · Event Date: August 7, 2026 Summary China’s NMPA accepted Alebund Pharmaceuticals’ new drug application for AP301, a non-absorbed fiber-iron phosphate binder for hyperphosphatemia…